These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10064076)

  • 1. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.
    Zorn E; Hercend T
    Eur J Immunol; 1999 Feb; 29(2):602-7. PubMed ID: 10064076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation.
    Zorn E; Hercend T
    Eur J Immunol; 1999 Feb; 29(2):592-601. PubMed ID: 10064075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.
    Ma W; Vigneron N; Chapiro J; Stroobant V; Germeau C; Boon T; Coulie PG; Van den Eynde BJ
    Int J Cancer; 2011 Nov; 129(10):2427-34. PubMed ID: 21207413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
    Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
    Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
    Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
    Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
    J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
    J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
    Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
    Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Vantomme V; Boël P; De Plaen E; Boon T; van der Bruggen P
    Cancer Immun; 2003 Dec; 3():17. PubMed ID: 14664500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
    Lonchay C; van der Bruggen P; Connerotte T; Hanagiri T; Coulie P; Colau D; Lucas S; Van Pel A; Thielemans K; van Baren N; Boon T
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
    Traversari C; van der Bruggen P; Luescher IF; Lurquin C; Chomez P; Van Pel A; De Plaen E; Amar-Costesec A; Boon T
    J Exp Med; 1992 Nov; 176(5):1453-7. PubMed ID: 1402688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
    Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
    Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.